Table 2.
Follow-up data, outcomes and predictors.
| Echo data - 6 months |
Univariate regression^ |
Multivariate regression^ |
|||||
|---|---|---|---|---|---|---|---|
| Variable | mean (SD) | β | OR (95% CI) | P | β | OR (95% CI) | p |
| LV-EDVi∗ | 44.4 (4.1) | 0.18 | 1.2 (1–1.4) | <0.01 | 0.08 | 1.05 (0.7–1.2) | 0.12 |
| LV-ESVi∗ | 22.1 (3.8) | 0.13 | 1.1 (1–1.6) | 0.01 | 0.05 | 1.02 (0.4–1.5) | 0.23 |
| LAVi∗ | 22.7 (2.7) | 0.23 | 1.3 (1.1–1.5) | <0.01 | 0.12 | 1.18 (1.1–1.9) | 0.04 |
| LVEF (%) | 50.3 (4.5) | −0.36 | 0.7 (0.5–0.9) | <0.01 | −0.15 | 0.8 (0.6–1.1) | 0.09 |
| Mitral E/A | 1.6 (0.3) | −0.35 | 0.7 (0.2–1.8) | 0.46 | |||
| RVFAC (%) | 42.2 (3.5) | −0.29 | 0.7 (0.6–0.9) | <0.01 | −0.21 | 0.7 (0.5–0.9) | 0.02 |
| Outcomes |
Univariate regression |
||||
|---|---|---|---|---|---|
| Endpoints | N (%) | Variable | β | OR (95% CI) | p |
| Death | 2 (4.7%) | Bromocriptine (yes = 1)# | −0.49 | 0.6 (0.1–2.2) | 0.44 |
| poor LV recovery | 11 (25.6%) | postpartum Δ (yes = 1) | 0.27 | 1.3 (0.3–5.3) | 0.70 |
| re-hospitalization | 4 (9.3%) | Age (1unit = 1) | 0.08 | 1.1 (0.8–1.4) | 0.56 |
| Composite | 14 (32.5%) | HTN-CD (yes = 1) | 1.24 | 3.4 (0.7–15.9) | 0.10 |
| Full LV recovery | 26 (60.5%) | Inotropic therapy (yes: 1) | 0.82 | 2.2 (0.4–12.5) | 0.31 |
| Partial LV recovery | 4 (9.3%) | Parity | −0.03 | 0.9 (0.4–2.1) | 0.93 |
∗in ml/m2; ^ with at presentation data; Δ: diagnosis; # of 35 patients discharged with bromocriptine only 19 patients used the drug for >/ = 1 week (54% adherence) and remaining (16/35) did-not used bromocriptine though prescribed; so, these 16 patients (prescribed but not used) and 5 patients (not prescribed) were taken as control (total = 21 [No = 0]) and remaining patients (19: during follow-up and 3: within hospital) were regarded as study group (total = 22 [Yes = 1]: mean duration of use - 2.2 weeks).